Brian Druker, M.D., head of OHSU’s Knight Cancer Institute, has been awarded the prestigious 2012 Japan Prize in Healthcare and Medical Technology for pioneering the development of targeted cancer drugs. Dr. Druker shares the Japan Prize with two other scientists who have revolutionized the way we think about cancer treatment: Nicholas B. Lydon, Ph.D., founder and director of Blueprint Medicines, and Janet D. Rowley, M.D., Blum-Riese Distinguished Service Professor of Medicine, Molecular Genetics & Cell Biology and Human Genetics at The University of Chicago.
Dr. Druker is best known for his role in developing Gleevec, a drug that treats chronic myeloid leukemia by blocking the protein that causes cancerous white blood cells to proliferate while leaving non-cancerous cells unharmed. In 2009, he received the Lasker-DeBakey Award for Clinical Medical Research. Today, Dr. Druker continues to help the Knight Cancer Institute grow as an international leader in personalized cancer medicine.
“My goal going forward,” he says, “Is to advance science so that someday there will be a targeted therapy to shut down every form of cancer.”